Finally, to demonstrate these effects were specific in ALK-activated NSCLC, MYCBP was effectively silenced in the EGFR mutant cell line HCC827 and treated with crizotinib (Supplementary Figure 1). Here, ALK is linked to non-small cell lung carcinoma.